Abstract

Disclosed is an immunoactivator that is capable of enhancing induction of both humoral immunity and cellular immunity and contains an active ingredient derived from cell walls (derived from a natural product); a vaccine adjuvant; and a method for inducing immunity including administering the immunoactivator. Theimmunoactivator contains, as an active ingredient, particles having a maximum diameter within a range of 1 to 800 nm, wherein the particles comprise cell-wall-derived polysaccharides.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/09 - Streptococcus
• A61P 37/04 - Immunostimulants

Abstract

A blood vessel segment discrimination system recognizes a three-dimensional structure of an abdomen of the patient, generates a depth image of the abdomen of the patient from the three-dimensional structure of the abdomen of the patient, generates a training data set used for training of a deep learning model, and discriminates an aortic segment of the patient using a trained deep learning model. A training data set generation unit generates the three-dimensional structure of the abdominal surface for learning from an abdominal CT image or the like of a person different from a patient who is a discrimination target of the aortic segment by the blood vessel segment discrimination device, generates a depth image for training from the three-dimensional structure of the abdominal surface for training, and generates a training data set showing a correspondence relationship between each pixel in the depth image for training and any of an aortic Zone 1, an aortic Zone 2, an aortic Zone 3, and another segment other than those Zones, based on the abdominal CT image.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/03 - Computed tomography [CT]
• G06T 7/11 - Region-based segmentation
• G06T 7/149 - SegmentationEdge detection involving deformable models, e.g. active contour models
• G06T 11/00 - 2D [Two Dimensional] image generation
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 20/64 - Three-dimensional objects

Abstract

Provided is a perspective inspection instrument 1 that is capable of accurately measuring a fusion maintenance capacity and that enables reduction in size and weight.　The perspective inspection instrument 1 includes a hand-held body 2. The body 2 includes: a window part 3 in which two light-transmitting members 8 and 9 are arranged to be overlapped; and a variable mechanism 11 that cooperates with the two light-transmitting members 8 and 9 to continuously vary the transmittance of light transmitted through the window part 3.

IPC Classes  ?

• A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus

Abstract

Provided is a cancer-associated fibroblast inhibitor, particularly a cancer-associated fibroblast inhibitor capable of augmenting the anti-cancer effects of anti-cancer agents.　The cancer-associated fibroblast inhibitor contains a PDGFR inhibitor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/14 - Drugs for genital or sexual disordersContraceptives for lactation disorders, e.g. galactorrhoea
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is an ophthalmologic examination instrument capable of performing a plurality of ophthalmologic function examinations.　An ophthalmologic examination instrument 1 comprises a hand-held body 2. The body 2 comprises a plurality of examination windows 22, 38 which enable ophthalmologic function examinations. The plurality of examination windows 22, 38 include pairs of window parts 20, 21, 30, 37, each pair being arranged with an interpupillary distance therebetween.

IPC Classes  ?

• A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
• A61B 3/11 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring interpupillary distance or diameter of pupils

Abstract

Provided are: a novel strain of an aflatoxin production-inhibiting bacterium which is a novel microorganism having a high aflatoxin production-inhibiting activity; a method for efficiently producing an inhibitor that includes an aflatoxin production inhibitor produced by an aflatoxin production-inhibiting bacterium including the novel strain and a chemical substance of which the effect is improved compared with the aflatoxin production inhibitor; and a method for controlling aflatoxin contamination using the aflatoxin production-inhibiting bacterium or the aflatoxin production inhibitor.　The aflatoxin production inhibitor comprises a culture product of Klebsiella sp. or Raoultella sp. or a compound represented by general formula (1) (wherein R represents a linear or branched C1-4 alkyl group).

IPC Classes  ?

• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01N 43/60 - 1,4-DiazinesHydrogenated 1,4-diazines
• A01P 3/00 - Fungicides
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 35/74 - Bacteria
• A61P 31/04 - Antibacterial agents
• A61P 39/02 - Antidotes
• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• C12N 1/20 - BacteriaCulture media therefor
• C12P 13/00 - Preparation of nitrogen-containing organic compounds

Abstract

A photovoltaic module abnormality determination system that determines presence or absence of an abnormality in a parallel resistance component of each of a plurality of photovoltaic cells connected in series to constitute a photovoltaic module, acquires an output current of the photovoltaic module during power generation, acquires a light shielding rate of a determination target photovoltaic cell for the presence or absence of the abnormality in a parallel resistance component, determines that the abnormality is not present in the parallel resistance component of the determination target photovoltaic cell in a case where a light shielding rate range of output current change, in which the output current of the photovoltaic module changes in a case where the light shielding rate of the determination target photovoltaic cell is changed, is between a light shielding rate of 0 and 1 of the determination target photovoltaic cell, and determines that the abnormality is present in the parallel resistance component of the determination target photovoltaic cell in a case where a light shielding rate range of non-output current change, in which the output current of the photovoltaic module hardly changes even in a case where the light shielding rate of the determination target photovoltaic cell is changed, is between the light shielding rate of 0 and 1 of the determination target photovoltaic cell.

IPC Classes  ?

• H02S 50/10 - Testing of PV devices, e.g. of PV modules or single PV cells

Abstract

Lipomycesstarkeyistarkeyi) strain that, as a consequence of undergoing main culture at 32-35°C after pre-culture at 23-26°C, is arrested for synchronization within G1 phase, or a Lipomyces starkeyi strain that, as a consequence of undergoing main culture at 30-32°C after pre-culture at 20-23°C, is arrested for synchronization within G2/M phase.

IPC Classes  ?

• C12N 1/16 - YeastsCulture media therefor
• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats

Abstract

Lipomycesstarkeyistarkeyi bacterial strain with the accession number NITE BP-03940.

IPC Classes  ?

• C12N 1/16 - YeastsCulture media therefor
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil

Abstract

A monitoring system includes a wearable terminal and a management server, in which the wearable terminal includes a detection unit, a score calculation unit, an alert output unit, and a transmission unit, the management server includes a reception unit and an output unit, in a case where a severity evaluation score calculated based on biological information of a wearer of the wearable terminal is equal to or more than a threshold value, the alert output unit outputs a consciousness disorder evaluation alert, the detection unit detects the biological information of the wearer of the wearable terminal and a reaction of the wearer of the wearable terminal to the output consciousness disorder evaluation alert, and the score calculation unit calculates the severity evaluation score including an evaluation of a consciousness disorder based on the detected biological information of the wearer of the wearable terminal and the detected reaction of the wearer of the wearable terminal to the consciousness disorder evaluation alert.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

An intraocular illumination device includes a fiber that guides light from a light source, and a holder that is disposed between an objective lens of a microscope and an eye during eye surgery or examination and supports a tip portion of the fiber. The tip portion of the fiber is provided with a reflecting portion that reflects the light guided through the fiber toward an inside of the eye.

IPC Classes  ?

• G02B 21/06 - Means for illuminating specimen
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 90/20 - Surgical microscopes characterised by non-optical aspects
• A61F 9/007 - Methods or devices for eye surgery
• G02B 21/00 - Microscopes

Abstract

The purpose of the present invention is to provide a detection device that can detect a nucleic acid without depending on the skill or the like of a user, a detection method that uses the detection device, and a heating device that heats the detection device.　This detection device (1) detects an amplified nucleic acid generated from a target nucleic acid included in a sample and has a sample placement member (22) at which the sample is placed, a test piece (29) used for detection of the amplified nucleic acid, amplification members (50, 51, 52, 53) to which is fixed a reagent used to generate the amplified nucleic acid from the target nucleic acid, and supply paths (19, 25, 26, 27, 28) that supply the amplified nucleic acid toward the test piece, the amplification members being provided at the supply paths.

IPC Classes  ?

• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

A medical image diagnostics assistance device (1) for assisting diagnosis of a medical image includes a classification model (1A) for classifying at least presence or absence of a disease from the medical image, a prediction unit (11) that carries out prediction using the classification model (1A), and a learning unit (12) that carries out supervised learning of the classification model (1A). In the supervised learning, a training medical image for which at least the presence or absence of the disease is previously known is used as supervised data. The classification model (1A) is constructed by a convolutional neural network (1A1) and an attention branch network (1A2) that visualizes an interest region of the convolutional neural network (1A1). In a stage where the supervised learning is carried out, the attention branch network (1A2) is provided with preliminary information indicating a classification region which is a region required for classifying the presence or absence of the disease on the training medical image.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

This blood pressure measurement device comprises: a pressure application unit for applying pressure to a site of a subject so as to stop blood flow; a light detection unit for detecting transmitted light that has passed through a more peripheral site than said site; and a control unit for determining an attenuation stop time at which the transmitted light transitions from an attenuation stage where the transmitted light attenuates to an attenuation stop stage where the attenuation of the transmitted light stops in a pressure rise stage where the pressure rises, and outputting a blood pressure measurement value on the basis of the pressure at the attenuation stop time.

IPC Classes  ?

• A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers

Abstract

Provided is a more inexpensive and rapid method for differentiating between a sensitive strain and a resistant strain of Trichophyton indotineae. The differentiating method comprises a step for preparing a genomic DNA sample from differentiation subject T. indotineae; and a step for carrying out a nucleic acid amplification reaction using the genomic DNA sample as a template and (1) a combination of a first forward primer containing a base sequence complementary to an antisense strand of a 3'-side region of CYP51B gene and a first reverse primer containing a base sequence complementary to a sense strand of a 5'- side region of the CYP51B gene, and/or a combination of a second forward primer containing a base sequence complementary to the sense strand 5' non-translated region of FYV4 gene and a second reverse primer containing a base sequence complementary to the sense strand 5' non-translated region of CHKB gene, and analyzing whether or not a nucleic acid amplification product of the expected size is present.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

A wound treatment device (1) comprises a transfer tube (2) of which one end (2a1) is inserted into the body of a patient and which transfers exudate produced inside the body to outside the body, and a manual suction pump (3) that is connected to another end (2b2) of the transfer tube (2) outside the body, and that suctions the exudate into the interior through the transfer tube (2). The suction pump (3) includes: a storage part (3a), the internal space of which is set to negative pressure by means of elastic recovery after deformation due to external pressure, and which suctions the exudate in body into the internal space through the transfer tube (2), and stores the exudate; a discharge part (3b) provided to be openable/closeable and capable of discharging the fluid in the internal space of the storage part (3a); and a check valve (3c) provided at a connection position with the transfer tube (2) and preventing backflow of the fluid from the internal space of the storage part (3a) to the transfer tube (2). A flow path for the exudate is formed inside the transfer tube (2), and a first opening with which it is possible to access the flow path is formed in addition to end openings respectively formed in the one end (2a1) and the other end (2b2) of the transfer tube (2).

IPC Classes  ?

• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

This questionnaire comprises a question column where question items are listed and a column for answers to the question items. The question items include the following question items (1) to (5). Question item (1): a question about the presence or absence of asthma history. Question item (2): a question about the presence or absence of wheezing. Question item (3): a question about the presence or absence of breathing difficulty at rest. Question item (4): a question about the presence or absence of awakening at night due to breathlessness or coughing. Question item (5): a question about the presence or absence of symptoms such as coughing or shortness of breath depending on weather or season.

IPC Classes  ?

• B42D 15/00 - Printed matter of special format or style not otherwise provided for

Abstract

A difference between a state of a first quantum bit and a state of a second quantum bit is accurately determined by comparing a signal obtained by amplifying a signal indicating the state of the first quantum bit with a signal obtained by amplifying a signal indicating the state of the second quantum bit, and specifically, an input signal inverted with respect to an input signal of a first quantum circuit is set to an input signal of a second quantum circuit such that an output of the first quantum circuit and an output of the second quantum circuit are inverted between logical values of 0 and 1 through a determination unit, so that an accuracy rate of readout of a state of a quantum bit is improved. A quantum device includes a first quantum circuit, a second quantum circuit, and a latch circuit connected to the first quantum circuit and the second quantum circuit, in which the latch circuit has a function of latching a state of a first quantum bit output from the first quantum circuit and amplifying a signal indicating the state of the first quantum bit, and a function of latching a state of a second quantum bit output from the second quantum circuit and amplifying a signal indicating the state of the second quantum bit.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers

Abstract

This method for producing a compound includes a step of obtaining a compound represented by general formula (1) by reacting a compound represented by general formula (2) with a compound represented by general formula (3) in the presence of a Lewis acid.

IPC Classes  ?

• C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
• C07B 61/00 - Other general methods
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

A learning analysis device includes a playback operation information acquisition unit configured to acquire playback operation information in which a playback operation of the same learning content performed by each of a plurality of learners is recorded, a result information acquisition unit configured to acquire result information indicating a result of each of the plurality of learners in a test conducted after the playback operation is performed, a learning content information acquisition unit configured to acquire learning content information that is information indicating what is played back at each of a plurality of playback positions between a playback start position and a playback end position of the learning content, and an extraction processing unit configured to execute a process of extracting one or more playback positions from the plurality of playback positions between the playback start position and the playback end position of the learning content based on a difference between the playback operation information of a learner having a test result greater than or equal to a first threshold value and the playback operation information of a learner having a test result less than the first threshold value.

IPC Classes  ?

• G09B 5/06 - Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
• G09B 7/04 - Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by the student characterised by modifying the teaching programme in response to a wrong answer, e.g. repeating the question, supplying a further explanation

Abstract

A semiconductor quantum device (1) according to the present disclosure comprises: a transistor structure (T) having a source (S), a drain (D), and a gate (G1); one or more quantum dot structures (3-1 to 3-n) where charge localization is possible; and quantum bit control current lines (5-1 to 5-n, 6-1 to 6-n) capable of changing the charging state in the quantum dot structures. The quantum dot structures and the quantum bit control current lines are disposed in the same layer. The transistor structure and the quantum dot structures are stacked in a stacking direction on a substrate (2).

IPC Classes  ?

• H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• H01L 29/66 - Types of semiconductor device
• H01L 29/82 - Types of semiconductor device controllable by variation of the magnetic field applied to the device
• H10B 43/20 - EEPROM devices comprising charge-trapping gate insulators characterised by three-dimensional arrangements, e.g. with cells on different height levels
• H10B 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

The present invention provides an expression vector carrying a gene encoding LHFPL6 protein and a gene encoding TM7SF3 protein. The present invention also provides a vector set comprising an expression vector carrying a gene encoding LHFPL6 protein and an expression vector carrying a gene encoding TM7SF3 protein. The present invention further provides a method for searching for a transporter protein, the method comprising: bringing a cell in which the transport protein is expressed on a cell membrane thereof into contact with a substrate for the transporter protein into which a photoreactive group is introduced, under the irradiation with light; and disrupting the cell after the contact to prepare a cell membrane fraction, and then performing an analysis by SWATH-MS method using the cell membrane fraction, and then selecting a candidate protein for the transporter.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 213/82 - AmidesImides in position 3
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

An abnormality determination system for a photovoltaic module determines the presence or absence of an abnormality in each of a plurality of photovoltaic cells constituting the photovoltaic module and connected in series; controls an irradiation state of incident light on a photovoltaic cell to be subjected to determination between at least a first irradiation state and a second irradiation state in which a short-circuit current of the photovoltaic cell to be subjected to determination is larger than a short-circuit current of the photovoltaic cell to be subjected to determination in the first irradiation state; irradiates the photovoltaic cell to be subjected to determination with modulated light different from the incident light; detects a minute change in an output current of the photovoltaic module in accordance with the irradiation of the photovoltaic cell to be subjected to determination with the modulated light; outputs a detection result as a phase detection unit output; calculates a ratio between a phase detection unit output in the first irradiation state and a phase detection unit output in the second irradiation state; and compares the ratio calculated with a threshold value set in advance.

IPC Classes  ?

• H02S 50/15 - Testing of PV devices, e.g. of PV modules or single PV cells using optical means, e.g. using electroluminescence

Abstract

Provided is a new pharmaceutical composition for treating or preventing arteriosclerosis. The pharmaceutical composition contains, as an active ingredient, a FoxO1 inhibitor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This surgical microscope system comprises: a surgical microscope body that has an observation optical system comprising at least an objective lens; and an auxiliary image capturing device that has at least an image capturing part and a lighting part. The surgical microscope system captures an image of a surgical field while the auxiliary image capturing device is connected to a surgical tool held by a surgeon or a surgical assistant.

IPC Classes  ?

• A61B 90/20 - Surgical microscopes characterised by non-optical aspects

Abstract

According to an embodiment, an evaluation system for evaluating a target member is provided with an information processing device including a processor, wherein: in a first acquisition step, the processor acquires reference information relating to a relationship between a first physical quantity and a second physical quantity relating to a reference material, wherein a target material forming the target member and the reference material both belong to a prescribed material group, and the first physical quantity and the second physical quantity relating to the reference material are different physical quantities relating to creep testing of a reference member formed from the reference material; in a second acquisition step, the processor acquires the first physical quantity relating to creep testing performed with respect to the target member; and in an evaluation step, the processor evaluates the second physical quantity of the target member on the basis of the reference information and the first physical quantity of the target member.

IPC Classes  ?

• G01N 3/00 - Investigating strength properties of solid materials by application of mechanical stress
• G01N 3/14 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces generated by dead weight, e.g. pendulumInvestigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces generated by spring tension

Abstract

In order to provide an immunoactivator capable of enhancing both humoral immunity and cellular immunity, the active ingredient of the immunoactivator being derived from cell walls (derived from a natural product), to provide a vaccine adjuvant, and to provide a method for inducing immunity, the method having a step for administering the immunoactivator, an immunoactivator according to the present invention has particles having a maximum diameter within the range of 1-800 nm as the active ingredient, the particles being composed of cell-wall-derived polysaccharides.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 36/06 - Fungi, e.g. yeasts
• A61K 36/484 - Glycyrrhiza (licorice)
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

A blood vessel demarcation discernment system according to the present invention recognizes a three-dimensional structure of an abdominal surface of a patient, generates a depth image of the abdominal surface of the patient from the three-dimensional structure of the abdominal surface of the patient, generates a training dataset to be used in training a deep learning model, and uses a trained deep learning model to discern an aorta demarcation of a patient. A training dataset generation unit generates a three-dimensional structure of an abdominal surface for training from abdominal CT images or the like of a person differing from the patient for which the aorta demarcation is to be discerned by the blood vessel demarcation discernment device, generates a depth image for training from the three-dimensional structure of the abdominal surface for training, and on the basis of the abdominal CT images, generates a training dataset indicating a correspondence between each pixel in the depth image for training and an aorta Zone 1, an aorta Zone 2, an aorta Zone 3, and any other zone.

IPC Classes  ?

• A61B 6/03 - Computed tomography [CT]
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

Abstract

Provided is a retinal vasodilator containing nobiletin. Also provided is a pharmaceutical composition for treating or preventing retinal circulatory disorders, the composition containing said retinal vasodilator and a pharmaceutically acceptable carrier.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 9/08 - Vasodilators for multiple indications
• A61P 27/02 - Ophthalmic agents

Abstract

Provided a novel miR-96-5p inhibitor that is more effective than an antisense oligonucleotide against miR-96-5p, and a novel pharmaceutical composition comprising the same. The miR-96-5p inhibitor comprises a peptide nucleic acid moiety comprising a nucleotide sequence complementary to miR-96-5p.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

This solar battery module abnormality determination system determines the presence or absence of an abnormality in a parallel resistance component in each of a plurality of solar battery cells that are connected in series and that constitute a solar battery module. The solar battery module abnormality determination system: acquires an output current of the solar battery module during power generation; acquires a light shielding rate of a determination target solar battery cell for which the presence or absence of an abnormality in a parallel resistance component is to be determined; determines that there is no abnormality in a parallel resistance component in the determination target solar battery cell when the range of an output-current-changing light shielding rate, at which the output current of the solar battery module changes as the light shielding rate of the determination target solar battery cell is changed, falls between zero and 1 of the light shielding rate of the determination target solar battery cell; and determines that there is an abnormality in a parallel resistance component in the determination target solar battery cell when the range of a non-output-current-changing light shielding rate, at which substantially no output current of the solar battery module changes even as the light shielding rate of the determination target solar battery cell is changed, falls between zero and 1 of the light shielding rate of the determination target solar battery cell.

IPC Classes  ?

• H02S 50/00 - Monitoring or testing of PV systems, e.g. load balancing or fault identification

Abstract

To provide an adjuvant containing lipid particles having a higher immune response inducing ability (preferably, Th1-type immune response inducing ability). This adjuvant contains lipid particles containing a cationic lipid represented by general formula (1).

IPC Classes  ?

• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 37/04 - Immunostimulants

Abstract

A quantum device includes a transistor structure section having a source, a drain, and a gate, one or more quantum dot structure sections in which a charge is localizable, and a quantum bit control current line configured to change a state of the charge in the quantum dot structure section.

IPC Classes  ?

• H01L 29/12 - Semiconductor bodies characterised by the materials of which they are formed
• H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions

Abstract

Provided is a protein having glucocerebrosidase activity and further having thermostability. The object is attained by a protein which is derived from a plant, belongs to glycoside hydrolase family 1 (GH1), and has glucocerebrosidase activity.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 13/02 - Amides, e.g. chloramphenicol
• A23L 33/185 - Vegetable proteins
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof

Abstract

A monitoring system according to the present invention comprises a wearable terminal and a management server. The wearable terminal comprises a detection unit, a score calculation unit, an alert output unit, and a transmission unit, and the management server comprises a reception unit and an output unit. If an illness severity assessment score calculated on the basis of biometric information of a wearer of the wearable terminal is equal to or greater than a threshold value, the alert output unit outputs a consciousness impairment assessment alert. The detection unit detects the biometric information of the wearer of the wearable terminal and the reaction of the wearer of the wearable terminal to the consciousness impairment assessment alert that was output. The score calculation unit calculates, on the basis of the detected biometric information of the wearer of the wearable terminal and the reaction of the wearer of the wearable terminal to the consciousness impairment assessment alert, an illness severity assessment score that includes an assessment of consciousness impairment.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G08B 21/02 - Alarms for ensuring the safety of persons
• G08B 25/04 - Alarm systems in which the location of the alarm condition is signalled to a central station, e.g. fire or police telegraphic systems characterised by the transmission medium using a single signalling line, e.g. in a closed loop
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance

Abstract

This operating voltage estimation device irradiates a multi-junction solar cell with color bias light, calculates an external quantum efficiency spectrum of each sub-cell under irradiation with the color bias light, irradiates the multi-junction solar cell, which is being operated by solar radiation, with micro-intensity monochromatic modulated light during estimation of the operating voltage of each sub-cell, and selects a wavelength of the monochromatic modulated light. During irradiation with the monochromatic modulated light, a phase detection unit receives, as an input, a reference signal indicating a phase of the monochromatic modulated light, and a signal indicating an output current of the multi-junction solar cell into which is mixed a component that is synchronous with the monochromatic modulated light in accordance with the operating voltage of each sub-cell of the multi-junction solar cell. The phase detection unit extracts and outputs the component that is synchronous with the monochromatic modulated light mixed into the output current of the multi-junction solar cell. A differential resistance corresponding to the operating voltage of each sub-cell is calculated on the basis of the output component that is synchronous with the monochromatic modulated light, and the operating voltage of each sub-cell is calculated on the basis of the calculated differential resistance.

IPC Classes  ?

• H02S 50/10 - Testing of PV devices, e.g. of PV modules or single PV cells

Abstract

This surgical digital microscope system comprises: an imaging unit for capturing a digital image of a treatment site of a patient; a first head-mounted display; and a second head-mounted display. The first head-mounted display comprises a first detection unit for detecting an input operation of the wearer thereof, and a first display unit for displaying a digital image captured by the imaging unit, in accordance with an input operation of the wearer of the first head-mounted display detected by the first detection unit. The second head-mounted display comprises a second detection unit for detecting an input operation of the wearer thereof, and a second display unit for displaying a digital image captured by the imaging unit, in accordance with an input operation of the wearer of the second head-mounted display detected by the second detection unit.

IPC Classes  ?

• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes
• A61B 90/20 - Surgical microscopes characterised by non-optical aspects

Abstract

Provided are pluripotent stem cell-derived cerebrovascular endothelial cells capable of accurately reflecting the transport function of human BBB and a production method of the same. The cerebrovascular endothelial cells are obtained by introducing MDR1 gene encoding P-gp into pluripotent stem cells and then inducing the differentiation into the cerebrovascular endothelial cells. The pluripotent stem cell-derived cerebrovascular endothelial cells of the present invention express P-gp at a high level, have a high barrier function, and retain an excellent function as a drug efflux transporter. The pluripotent stem cell-derived cerebrovascular endothelial cells of the present invention have an excellent drug efflux transporter function that has never been achieved by immortalized cerebrovascular endothelial cell lines established from human cerebrovascular endothelial cells. Moreover, the pluripotent stem cell-derived cerebrovascular endothelial cells of the present invention accurately reflect the transport function of human BBB and thus make it possible to overcome the problem of the difficulty of obtaining cerebrovascular endothelial cells having comparable properties occurring in primary cerebrovascular endothelial cells.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Provided is a new vitamin D derivative that is useful for preventing or treating cancer or psoriasis. The vitamin D derivative is a compound represented by general formula (I) (in the formula, X represents a linear or branched alkyl group having 1-8 carbon atoms and optionally substituted with a hydroxyl group, or represents a linear or branched alkenyl group having 1-8 carbon atoms and optionally substituted with a hydroxyl group, and Y represents a linear or branched alkyl group that has 1-12 carbon atoms, that is substituted with at least one halogen atom, and that is optionally substituted with a hydroxyl group).

IPC Classes  ?

• C07C 401/00 - Irradiation products of cholesterol or its derivativesVitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 17/06 - Antipsoriatics
• A61P 35/00 - Antineoplastic agents

Abstract

This intraocular illumination device comprises: a fiber for guiding light from a light source; and a holder which is disposed between an objective lens of a microscope and an eye during surgery or inspection of the eye and which supports the leading end of the fiber. Provided to the leading end of the fiber is a reflective part on which the light guided through the fiber is reflected toward the interior of the eye.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• F21S 2/00 - Systems of lighting devices, not provided for in main groups or , e.g. of modular construction
• F21V 8/00 - Use of light guides, e.g. fibre optic devices, in lighting devices or systems
• G02B 21/06 - Means for illuminating specimen
• F21Y 101/00 - Point-like light sources
• F21Y 115/10 - Light-emitting diodes [LED]

Abstract

A medical image diagnostics assistance device (1) comprises: a classification model (1A) for classifying at least presence or absence of disease from a medical image; a prediction unit (11) that carries out prediction using the classification model (1A); and a learning unit (12) that carries out supervised learning of the classification model (1A). The supervised learning uses a training medical image for which at least presence or absence of disease is known as teacher data. The classification model (1A) is composed of a convolutional neural network (1A1) and an attention branch network (1A2) that visualizes a region of interest of the convolutional neural network (1A1). At the stage of carrying out the supervised learning, the attention branch network (1A2) is given preliminary information indicating a classification region, which is a region in the training medical image required for classification of presence or absence of disease.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/03 - Computed tomography [CT]

Abstract

According to an embodiment, there are provided a screening culture medium that enables a convenient and quick examination for the presence of Candida auris, and a screening method. According to at least one embodiment, the screening culture medium contains an enzyme substrate, in which the screening culture medium is used for screening Candida auris based on an ability to degrade the enzyme substrate, the enzyme substrate including raffinose and xylose. According to another embodiment, the screening method uses the screening culture medium.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

A difference between a state of a first quantum bit and a state of a second quantum bit is accurately determined by comparing a signal obtained by amplifying a signal indicating the state of the first quantum bit and a signal obtained by amplifying a signal indicating the state of the second quantum bit, and more specifically, the accuracy rate of reading out the states of the quantum bits is improved by using an input signal obtained by inverting an input signal of a first quantum circuit as an input signal of a second quantum circuit, such that an output of the first quantum circuit and an output of the second quantum circuit are inverted between logical values 0 and 1 by way of a determining unit. A quantum device comprises a first quantum circuit, a second quantum circuit, and a latch circuit connected to the first quantum circuit and the second quantum circuit, where the latch circuit has a function of latching the state of a first quantum bit output from the first quantum circuit and amplifying a signal indicating the state of the first quantum bit, and a function of latching the state of a second quantum bit output from the second quantum circuit and amplifying a signal indicating the state of the second quantum bit.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

Provided is a plant variant having a higher glucosylceramide percentage content than conventional strains.　In the plant variant, the function of at least one gene encoding a protein that belongs to the glycoside hydrolase family-1 and that has a glucocerebrosidase activity is deficient or suppressed.

IPC Classes  ?

• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• A01H 1/00 - Processes for modifying genotypes
• A01H 1/06 - Processes for producing mutations, e.g. treatment with chemicals or with radiation
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 35/00 - Antineoplastic agents
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• A61K 131/00 - Containing or obtained from seeds, nuts, fruits or grains

Abstract

A method for producing an alkali metal halide that includes a step for reacting a solid or liquid halogen-containing organic compound with a molten alkali metal hydroxide.

IPC Classes  ?

• C01D 3/02 - Fluorides
• C01D 3/04 - Chlorides
• C01F 11/20 - Halides
• C01F 11/22 - Fluorides
• C01F 11/24 - Chlorides
• C08J 11/14 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with steam or water
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• A62D 3/00 - Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances
• B09B 3/00 - Destroying solid waste or transforming solid waste into something useful or harmless

Abstract

An abnormality determination system for a solar battery module according to the present invention determines the presence or absence of an abnormality in each of a plurality of solar battery cells constituting a solar battery module and connected in series. This abnormality determination system controls an irradiation state of incident light on a solar battery cell to be subjected to the determination between at least a first irradiation state and a second irradiation state in which the short-circuit current of the solar battery cell to be subjected to the determination is larger than in the first irradiation state, irradiates the solar battery cell to be subjected to the determination with modulated light different from the incident light, detects a minute change in the output current of the solar battery module in accordance with the irradiation of the solar battery cell to be subjected to the determination with the modulated light, outputs a result of the detection as a phase detection unit output, calculates a ratio between the phase detection unit output in the first irradiation state and the phase detection unit output in the second irradiation state, and compares the calculated ratio and a threshold value set in advance.

IPC Classes  ?

• H02S 50/10 - Testing of PV devices, e.g. of PV modules or single PV cells
• G01M 11/00 - Testing of optical apparatusTesting structures by optical methods not otherwise provided for

Abstract

This radiation blocking plate (1) comprises: a first plate member (10) that is formed of a radiation blocking material for blocking radiation, and that is installed on a floor surface (F), with a principle surface (10a) facing a front/back direction; a second plate member (20) that is formed of a radiation blocking material for blocking radiation, that is provided at a higher position than the first plate member (10), with a principle surface (20a) facing in the front/back direction; and a middle member (30) that is formed of a radiation blocking material for blocking radiation, that is provided between the first panel member (10) and the second panel member (20), that includes a narrow part (31) having a right/left direction width smaller than the right/left direction width of the first plate member (10) and of the second plate member (20), and that includes an opening part (32) which is provided at least on one side, in the right/left direction, of the narrow part (31), and which opens in the front/back direction.

IPC Classes  ?

• G21F 1/08 - MetalsAlloysCermets, i.e. sintered mixtures of ceramics and metals
• G21F 3/00 - Shielding characterised by its physical form, e.g. granules, or shape of the material

Abstract

A detection method for pan-resistant K. pneumoniae comprising of: performing complete genome analysis of the bacteria contained in the sample; and comparing a nucleotide sequence contained in the obtained complete genome with nucleotide sequences of SEQ ID NO: 1 or 2, and determining whether or not the bacteria in the sample is pan-resistant K. pneumoniae based on the rate of agreement.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

An eye movement analysis system includes an image-capturing unit configured to capture a moving image including at least one of a right eye and a left eye of a subject and a comparison target on a surface of a face of the subject, and an analysis unit configured to analyze a movement of an eyeball of the at least one of the right eye and the left eye of the subject, based on a relationship between the at least one of the right eye and the left eye of the subject and the comparison target on the moving image captured by the image-capturing unit.

IPC Classes  ?

• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06F 3/0346 - Pointing devices displaced or positioned by the userAccessories therefor with detection of the device orientation or free movement in a 3D space, e.g. 3D mice, 6-DOF [six degrees of freedom] pointers using gyroscopes, accelerometers or tilt-sensors
• G06T 7/20 - Analysis of motion

Abstract

Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.

IPC Classes  ?

• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents
• C07C 33/14 - Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
• C07C 215/26 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
• C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
• C07D 257/04 - Five-membered rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07C 401/00 - Irradiation products of cholesterol or its derivativesVitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Abstract

The present invention provides a method for treating or preventing inflammation caused by neutrophils and a pharmaceutical composition for such treatment or prevention. Specifically, provided is a pharmaceutical composition or the like for treating or preventing inflammation caused by neutrophils that contains a complex in which lysozyme and chitosan are bonded.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A blood vessel harvesting system, which harvests blood vessels in a state of being covered by surrounding tissue, includes a separating device and a display device. The separating device includes a rod portion that is inserted into a living body, an optically transparent taper-shaped separating portion that is disposed at a distal end part of the rod portion, an endoscope portion that is disposed inside the rod portion and captures an endoscope image of an interior of the living body via the separating portion, and an ultrasound transceiver portion that is disposed on an outer peripheral surface of the rod portion, irradiates the interior of the living body with an ultrasonic wave, and receives a reflected wave from the interior of the living body. The display device matches a scale of the endoscope image with a scale of an ultrasound image acquired by the ultrasound transceiver portion and simultaneously displays the endoscope image and the ultrasound image side by side on the display screen, and the display device disposes the endoscope image and the ultrasound image on the display screen such that a point in the endoscope image indicating a predetermined position in the living body matches a point in the ultrasound image indicating the predetermined position on the display screen.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
• A61B 1/313 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

A method for estimating an operation voltage of a cell includes setting a state in which one cell is shielded from light; detecting a small change of an output current of a module in that state; irradiating another cell with modulated and detecting the small change of the output current light in that state; detecting an operation voltage of the module in that state; generating a first calibration line by connecting a first point and a second point which are plotted on coordinate axes representing a voltage and a relative ratio of a resistor; irradiating a cell the operation voltage of which is to be estimated with the modulated light and detecting the small change of the output current of the module in a state in which none of the cells is shielded from light; detecting the operation voltage of the module in that state; generating a second calibration line by connecting a third point and the second point which are plotted on the coordinate axes; calculating a value of the relative ratio of the resistor of the cell the operation voltage of which is to be estimated; and calculating a value of a voltage of a fourth point, which becomes the value of the relative ratio of the resistor and is provided on the second calibration line, as the operation voltage of the cell to be estimated.

IPC Classes  ?

• H02S 50/15 - Testing of PV devices, e.g. of PV modules or single PV cells using optical means, e.g. using electroluminescence
• G01R 31/3835 - Arrangements for monitoring battery or accumulator variables, e.g. SoC involving only voltage measurements
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery

Abstract

Provided are: a new miR-96-5p inhibitor that is more effective than an antisense oligonucleotide against miR-96-5p; and a pharmaceutical composition containing same.　The miR-96-5p inhibitor includes a peptide nucleic acid portion having a base sequence complementary to miR-96-5p.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
• A61P 23/02 - Local anaesthetics
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

Abstract

The purpose of the present invention is to provide: a novel deuterated labeling compound; and a production method therefor. The present invention provides: a deuterated labeling compound in which at least position β of a fatty acid is deuterated; and a production method for the deuterated labeling compound. The deuterated labeling compound according to the present invention is advantageous since the deuterated labeling compound can be widely used in analysis of metabolism and the like of lipids, fatty acids, and fatty acid-binding proteins. The deuterated labeling compound according to the present invention can be used as an internal standard substance for mass spectrometry in quantification of a lipid or a fatty acid-binding protein, or a metabolite thereof. The deuterated labeling compound according to the present invention can also be used as a metabolite marker in analysis of in vivo metabolism.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 51/347 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups
• C07C 53/126 - Acids containing more than four carbon atoms
• C07C 57/12 - Straight chain carboxylic acids containing eighteen carbon atoms
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 233/44 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
• C07B 61/00 - Other general methods
• C07D 215/40 - Nitrogen atoms attached in position 8
• C07C 67/20 - Preparation of carboxylic acid esters by conversion of a group containing nitrogen into an ester group from amides or lactams
• C07C 69/24 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
• C07C 69/587 - Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode

Abstract

This quantum device comprises: a transistor structure having a source, a drain, and a gate; one or more quantum dot structures whereby a charge can be localized; and a quantum dot control current line that makes it possible to change the state of a charge within the quantum dot structures.

IPC Classes  ?

• H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions
• H01L 21/336 - Field-effect transistors with an insulated gate
• H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate

Abstract

This intracorporeal insertion tube set comprises an intracorporeal insertion tube having a tube body and an inflation system, and a packaging bag that accommodates the intracorporeal insertion tube, wherein: the tube body comprises a distal-end section and a proximal-end section disposed on the opposite side to the distal end section; the inflation system comprises a cuff, an inflation line extending from the cuff, and a pilot balloon disposed on the opposite side to the cuff to be spaced apart from the inflation line, and the packaging bag is provided with a positioning part that causes the proximal-end section and the pilot balloon to be adjacent to each other in a state in which the intracorporeal insertion tube is accommodated in the packaging bag.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes

Abstract

This intracorporeal insertion tube set comprises: a tube body; an intracorporeal tube having a part to be coated that is the portion to which a lubricant is coated; and a packaging bag that accommodates the intracorporeal insertion tube, wherein the intracorporeal insertion tube set is provided with a lubricant supply part that supplies a lubricant to the part to be coated in a state in which the intracorporeal insertion tube is accommodated in the packaging bag.

IPC Classes  ?

• A61J 1/00 - Containers specially adapted for medical or pharmaceutical purposes
• A61M 16/04 - Tracheal tubes

Abstract

Provides is a more useful novel biomarker with which rheumatoid arthritis can be simply and accurately detected, in particular, a biomarker with which rheumatoid arthritis can be diagnosed at an early stage.　In a diagnostic method for rheumatoid arthritis according to the present invention, acrolein in a sample collected from a subject is measured.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

To provide a protein having glucocerebrosidase activity and also having thermostability. The aforementioned problem is solved by a protein that is plant-derived, belongs to the glycoside hydrolase family 1 (GH1), and has glucocerebrosidase activity.

IPC Classes  ?

• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A61K 36/42 - Cucurbitaceae (Cucumber family)
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
• A61K 36/88 - Liliopsida (monocotyledons)
• A61K 36/896 - Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 7/06 - Antianaemics
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention addresses the problem of providing a method for elucidating the correlation between an irritant for an organism and a produced substance that is produced within the organism due to the irritant, and of providing a method for screening, based on the knowledge yielded by the aforementioned method, irritants, produced substances, and their combinations. The problem is solved by the following: a method characterized by elucidating the correlation between an irritant and a produced substance by bringing the irritant into contact with the cells in the sac of a bubble eye goldfish and then quantitating the produced substance produced by these cells or the gene for the produced substance; and a method for screening, using the aforesaid method, irritants, produced substances, or "irritant/produced substance combinations".

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.

IPC Classes  ?

• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• A61K 9/107 - Emulsions
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a screening culture medium and a screening method that enable a quick and convenient check for the presence of Candida auris. The screening culture medium contains an enzyme substrate and is used to screen for Candida auris based on the ability to degrade the enzyme substrate. The enzyme substrate contains raffinose and xylose. The screening method uses the screening culture medium.

IPC Classes  ?

• C12N 1/16 - YeastsCulture media therefor
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor

Abstract

Even for the case where cells such as human epidermal keratinocytes form a dense colony, or the case where cell contours are indefinite, each of the cells is automatically tracked with high precision, and behavior of each cell is analyzed with good precision. There is provided a method for analyzing behavior of a cell, which comprises a detection step of detecting positions of a plurality of cells for every frame of time-lapse images, while determining whether a candidate region extracted from the frame is a cell region by using a dictionary containing image data of cell nuclei; and a tracking step of tracking each cell by using a state space model using position of a most adjacent cell within a predetermined distance from a predicted position as observation data. When any cell is not found within a certain distance from the predicted position, data are considered missing.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G06T 7/277 - Analysis of motion involving stochastic approaches, e.g. using Kalman filters

Abstract

Candida auris, including subjecting a nucleic acid sample obtained from a specimen to a nucleic acid amplification reaction by the LAMP method and detecting an amplification product, wherein, in the primer set to be used in the LAMP method, FIP is a polynucleotide including 5 to 20 nucleotides located on the 5′-terminal side and 5 to 20 nucleotides located on the 3′-terminal side in the nucleotide sequence represented by SEQ ID NO: 1, BIP is a polynucleotide including 5 to 20 nucleotides located on the 5′-terminal side and 5 to 20 nucleotides located on the 3′-terminal side in the nucleotide sequence represented by SEQ ID NO: 2, F3 is a polynucleotide including SEQ ID NO: 3, and B3 is a polynucleotide including SEQ ID NO: 4.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

This learning analysis device is provided with: a reproduction operation information acquisition unit which acquires reproduction operation information that records reproduction operations for the same learning content by a plurality of learners; a result information acquisition unit which acquires result information that indicates results of the plurality of respective learners in an examination conducted after the reproduction operations have been performed; a learning content information acquisition unit which acquires learning content information that is information indicating what is reproduced at each of a plurality of reproduction positions between a reproduction start position and a reproduction end position of the learning content; and an extraction processing unit which, on the basis of a difference between the reproduction operation information of a learner whose result of the examination is a first threshold value or more and the reproduction operation information of a learner whose result of the examination is less than the first threshold value, executes processing for extracting one or more reproduction positions from among the plurality of reproduction positions between the reproduction start position and the reproduction end position of the learning content.

IPC Classes  ?

• G09B 5/06 - Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
• G09B 19/00 - Teaching not covered by other main groups of this subclass
• H04N 5/76 - Television signal recording
• H04N 5/93 - Regeneration of the television signal or of selected parts thereof

Abstract

The present invention provides an oil/fat accumulation induction medium and an oil/fat accumulation induction method, which enable cost reduction of the medium itself and enable the oil/fat accumulation amount in cells to be increased.　The oil/fat accumulation induction medium contains a sugar but does not contain ammonium sulfate. The oil/fat accumulation induction method includes a step for performing culturing in said oil/fat accumulation induction medium.

IPC Classes  ?

• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
• C12N 1/16 - YeastsCulture media therefor

Abstract

Trichophyton gene.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates

Abstract

[Problem] To provide a novel medicine for preventing and/or treating influenza virus infection or corona virus infection. [Solution] According to the present invention, provided are an anti-influenza virus agent, an anti-corona virus agent and a prophylactic and/or therapeutic agent for influenza virus infection or corona virus infection, each comprising, as an active ingredient, one or more kinds of 15-membered ring macrolide compounds selected from the group consisting of compound 1 to compound 4, a salt thereof or a hydrate of the same.

IPC Classes  ?

• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

The present invention provides a composition having an antifungal activity without depending on conventional compositions having anticandidal activity or combinations of such compositions. The composition comprises a complex of lysozyme bonded to chitosan. The composition according to the present invention is applicable to candidiasis of the skin and mucous membranes, in particular, oral candidiasis and vagina candidiasis affecting a large number of patients and can ameliorate the symptoms of these diseases, heal the same and prevent infection of the same. The composition comprises a complex of lysozyme, which has been widely used as a highly safe natural food additive, with a polysaccharide and, therefore, can reassure patients who use the same and ease their burden. The composition according to the present invention comprises a complex of lysozyme, which is a highly safe natural food additive, with a polysaccharide and, therefore, can be safely used by patients without considering any risk.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/722 - ChitinChitosan
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61P 31/10 - Antimycotics
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Abstract

This determination device has: a pressure sensor for detecting the inner pressure of a cuff provided on a tracheal tube; and a determination unit for determining that the tracheal tube is being inserted or has been inserted into the esophagus on the basis of the inner pressure detected by the pressure sensor and a predetermined determination reference. The determination reference is determined on the basis of the difference between the inner pressure detected when the tracheal tube is inserted into the trachea and the inner pressure detected when the tracheal tube is inserted into the esophagus.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes

Abstract

This eyeball movement analysis system is provided with: an image capturing unit which captures a moving image including at least one among the right eye and the left eye of a subject, and a comparison target on the surface of the subject's face; and an analysis unit which analyzes the movement of the eyeball of the at least one among the right eye and the left eye of the subject on the basis of the relationship between the comparison target and the at least one among the right eye and the left eye of the subject in the moving image captured by the image capturing unit.

IPC Classes  ?

• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• G06F 3/0346 - Pointing devices displaced or positioned by the userAccessories therefor with detection of the device orientation or free movement in a 3D space, e.g. 3D mice, 6-DOF [six degrees of freedom] pointers using gyroscopes, accelerometers or tilt-sensors

Abstract

The present invention provides a method for treating or preventing inflammation caused by neutrophils and a pharmaceutical composition for such treatment or prevention. Specifically, provided is a pharmaceutical composition or the like for treating or preventing inflammation caused by neutrophils that contains a complex in which lysozyme and chitosan are bonded.

IPC Classes  ?

• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/00 - Drugs for dermatological disorders
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Abstract

The present invention includes: a step in which a full genome analysis of a bacterium that is included in a specimen is performed; and a step in which the base sequence of the obtained full genome and the base sequence of SEQ ID NO:1 or 2 are compared, and on the basis of the rate of correspondence, it is determined whether the bacterium in the specimen is pan-resistant K. pneumoniae.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 31/04 - Antibacterial agents
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

This blood vessel harvesting system, for harvesting blood vessels in a state of being covered by surrounding tissue, includes a separating device and a display device. The separating device comprises: a rod part inserted into a living body; an optically transparent taper-shaped separating part disposed at the distal end portion of the rod part; an endoscope unit disposed inside the rod part, capturing, through the separating part, an endoscope image of the interior of the living body; and an ultrasound transceiver unit disposed on the outer peripheral surface of the rod part transmitting ultrasound into the living body and receiving reflected waves from the interior of the living body. The display device matches the scale of the endoscope image with the scale of the ultrasound image acquired by the ultrasound transceiver unit and simultaneously displays the endoscope image and the ultrasound image side by side on a display screen, while positioning the endoscope image and the ultrasound image on the display screen in such a manner as to match, on the display screen, a point in the endoscope image indicating a predetermined position in the living body with a point in the ultrasound image indicating the predetermined position.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 17/3205 - Excision instruments

Abstract

This blood vessel harvesting system, for harvesting blood vessels in a state of being covered by surrounding tissue, includes a separating device and a display device. The separating device comprises: a rod part inserted into a living body; an optically transparent taper-shaped separating part disposed at the distal end portion of the rod part; an endoscope unit disposed inside the rod part, capturing, through the separating part, an endoscope image of the interior of the living body; and an ultrasound transceiver unit disposed on the outer peripheral surface of the rod part transmitting ultrasound into the living body and receiving reflected waves from the interior of the living body. The display device matches the scale of the endoscope image with the scale of the ultrasound image acquired by the ultrasound transceiver unit and simultaneously displays the endoscope image and the ultrasound image side by side on a display screen, while positioning the endoscope image and the ultrasound image on the display screen in such a manner as to match, on the display screen, a point in the endoscope image indicating a predetermined position in the living body with a point in the ultrasound image indicating the predetermined position.

IPC Classes  ?

• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
• A61B 17/3205 - Excision instruments

Abstract

△I△I) are set; irradiating a cell, the operation voltage of which is to be estimated, with the modulated light in a state in which none of the cells is shielded from light and detecting a small change of the output current of the module; detecting the operation voltage of the module in that state; generating a second calibration line (L2) by connecting a third point (P3) and the second point (P2) which are plotted on the coordinate axis; calculating a resistor relative ratio value of the cell, the operation voltage of which is to be estimated; and calculating a value of the voltage of a fourth point (P4) as an operation voltage of the cell to be estimated, said fourth point (P4) being a point that becomes the resistor relative ratio value and lies on the second calibration line (L2).

IPC Classes  ?

• H02S 50/10 - Testing of PV devices, e.g. of PV modules or single PV cells

Abstract

The present invention addresses the problem of providing a lactic acid bacterium having an excellent natural immune activation ability, a natural immune activating agent comprising a product, treatment product, etc. of the lactic acid bacterium as an active ingredient, and a preventive/therapeutic drug for infection and a food or beverage comprising the same, and also providing a preventive/therapeutic drug for infection comprising an active ingredient derived from the lactic acid bacterium and a food or beverage fermented with the use of the lactic acid bacterium. This problem is solved by: a lactic acid bacterium belonging to Weissella hellenica; a natural immune activating agent comprising dead cells of the lactic acid bacterium, a product of the lactic acid bacterium or a treatment product of the lactic acid bacterium as an active ingredient, wherein the treatment product of the lactic acid bacterium is a culture, culture supernatant, concentrate, pasted product, dried product, liquefied product, dilution, ground product, pasteurized processed product or culture extract of the lactic acid bacterium; and a preventive/therapeutic drug for infection characterized by comprising the natural immune activating agent and being to be used for preventing or treating infection with a pathogenic bacterium or virus.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A23C 11/10 - Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 37/04 - Immunostimulants
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention addresses the problem of providing a technology that can stably express the effect of an A-type CpG oligodeoxynucleotide. Said problem is solved by a lipid particle containing an A-type CpG oligodeoxynucleotide.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/133 - Unilamellar vesicles
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants

Abstract

The purpose of the present invention is to analyze the behavior of individual cells with high accuracy by automatically tracking each of the cells with high accuracy even when the cells form a dense colony like human epidermal keratinocytes or when the outline of each of the cells is indistinct. Provided is a method for analyzing the behavior of cells, comprising: a detection step of detecting the positions of multiple cells in each of frames of time lapse images, in which it is determined as to whether or not a candidate region extracted from the frames is a cell region using a dictionary including image date of the nuclei of the cells; and a tracking step of tracking each of the cells using a state space model wherein the position of a most nearest cell located within a predetermined distance from a prediction position is employed as observation data. When no cell is found within the predetermined distance from the prediction position, it is determined that data is missing.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G06T 7/00 - Image analysis
• G06T 7/277 - Analysis of motion involving stochastic approaches, e.g. using Kalman filters

Abstract

A tracheal tube insertion aid kit (1) assists in inserting a tracheal tube (9) from an oral cavity (B) of a patient (A) into an endotracheal space (E) through a glottis (D) using an indirect glottis viewing type laryngoscope (2) not equipped with the tracheal tube (9). The tracheal tube insertion aid kit (1) includes a guide tube (11) having flexibility and formed to be insertable into the endotracheal space (E) from the oral cavity (B) through the glottis (D), and a guide wire (12) formed to be insertable through the inside of the guide tube (11) and insertable into the endotracheal space (E) from the oral cavity (B) through the glottis (D).

IPC Classes  ?

• A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
• A61M 16/04 - Tracheal tubes

Abstract

A method for detecting Candida auris in which nucleic acid amplification is conducted by the LAMP method on a nucleic acid sample obtained from a specimen and the amplification product is detected, wherein the FIP in the primer set in the LAMP method is a polynucleotide including 5-20 bases on the 5' end side and 5-20 bases on the 3' end side of a base sequence shown by SEQ ID NO: 1, the BIP is a polynucleotide including 5-20 bases on the 5' end side and 5-20 bases on the 3' end side of a base sequence shown by SEQ ID NO: 2, F3 is a polynucleotide comprising SEQ ID NO: 3, and B3 is a polynucleotide comprising SEQ ID NO: 4.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

A rhinomanometry device according to the present invention is provided with a left nasal cavity tube having a subject-side end part and a sensor-side end part, a right nasal cavity tube having a subject-side end part and a sensor-side end part, a left nasal cavity pressure sensor for detecting the pressure in the left nasal cavity tube, and a right nasal cavity pressure sensor for detecting the pressure in the right nasal cavity tube, the diameter of the subject-side end part of the left nasal cavity tube inserted into the left nasal cavity of a subject being such that the left nasal cavity of the subject is not entirely occupied thereby, the diameter of the subject-side end part of the right nasal cavity tube inserted into the right nasal cavity of the subject being such that the right nasal cavity of the subject is not entirely occupied thereby, detection of the pressure in the left nasal cavity tube by the left nasal cavity pressure sensor and detection of the pressure in the right nasal cavity tube by the right nasal cavity pressure sensor being executed simultaneously and being continuously executable over a time in which sleep apnea can be evaluated.

IPC Classes  ?

• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
• A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing

Abstract

The purpose of the present invention is to provide a method for diagnosing tinea simply and rapidly, a method for detecting trichophyton, or a method for detecting a trichophyton gene. Using at least four types of specific primers designed on the basis of a DNA sequence of a trichophyton gene can simply and rapidly detect said trichophyton gene by means of a LAMP method.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/09 - Recombinant DNA-technology

Abstract

In one embodiment, the present invention provides a new marker, method, kit, etc., with which it is possible to determine an MLH1 methylation group at high accuracy. In one embodiment, the present invention relates to a marker for mutL homolog 1 (MLH1) methylation group determination, wherein the marker comprises any of (i)-(iii): (i) a nucleic acid molecule including a base sequence shown by SEQ ID NO: 1, (ii) a nucleic acid molecule including a base sequence in which one or several bases have been added, deleted, and/or substituted in SEQ ID NO: 1, and (iii) a fragment of a nucleic acid molecule of (i) or (ii) including one or more CpG sequences.

IPC Classes  ?

• C12N 15/12 - Genes encoding animal proteins
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12Q 1/42 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving phosphatase

Abstract

Provided are a kit for IgA nephropathy diagnosis, and an IgA nephropathy diagnostic agent, which include vimentin or a partial peptide thereof. Also provided is a data collection method for evaluating the possibility that a subject is affected by IgA nephropathy, said method comprising a step for measuring the antibody value of an anti-vimentin antibody in a blood sample of the subject.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

An objective of the present invention is to provide an eyeglass cover capable of being attached to frames or lenses having a variety of shapes. Provided is an eyeglass cover comprising: a main body part (11) positioned in proximity to one surface of one lens (22) of eyeglasses (20) comprising a pair of lenses (22) and a frame (21) supporting the lenses (22), said main body part (11) imparting an optical characteristic to a wearer of the eyeglasses (20) that differs from a situation where the lenses (22) are used without the cover; and a locking part (15) protruding from the main body part (11) toward the one surface side of the lens (22) and capable of locking either on an upper end part of a rim (23) of the frame (21) or an upper end part of the lens (22).

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• G02C 11/00 - Non-optical adjunctsAttachment thereof

Abstract

A vector for causing a desired gene linked downstream of a renal tubule cell-specific promotor to be expressed specifically in renal tubule cells, the vector comprising a viral vector having the renal tubule cell-specific promotor and the desired gene.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

This laying weight scale comprises: a right-side sensor part having a measurement surface; a left-side sensor part having a measurement surface; and a calculation unit that totals a load applied to the measurement surface of the right-side sensor part and a load applied to the measurement surface of the left-side sensor part, and calculates this total as the weight of a subject to be measured. The right-side sensor part and the left-side sensor part are separated from each other.

IPC Classes  ?

• G01G 19/44 - Weighing apparatus or methods adapted for special purposes not provided for in groups for weighing persons

Abstract

The present invention provides a composition having an antifungal activity without depending on conventional compositions having anticandidal activity or combinations of such compositions. The composition comprises a complex of lysozyme bonded to chitosan. The composition according to the present invention is applicable to candidiasis of the skin and mucous membranes, in particular, oral candidiasis and vagina candidiasis affecting a large number of patients and can ameliorate the symptoms of these diseases, heal the same and prevent infection of the same. The composition comprises a complex of lysozyme, which has been widely used as a highly safe natural food additive, with a polysaccharide and, therefore, can reassure patients who use the same and ease their burden. The composition according to the present invention comprises a complex of lysozyme, which is a highly safe natural food additive, with a polysaccharide and, therefore, can be safely used by patients without considering any risk.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/722 - ChitinChitosan
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61P 31/10 - Antimycotics
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Abstract

This ocular fundus imaging system comprises: an ocular fundus imaging camera body unit that images the ocular fundus of a subject; a forehead contact unit that contacts the forehead of the subject during imaging of the ocular fundus; a chin receiving unit that contacts the chin of the subject during imaging of the ocular fundus; a first pulse wave detection unit that is provided to the forehead contact unit; a second pulse wave detection unit that detects pulse waves at a location other than the forehead of the subject; and a control unit that controls the ocular fundus imaging camera body unit. The control unit comprises: a phase calculation unit that calculates, on the basis of the phase of pulse waves of the forehead of the subject that were detected by the first pulse wave detection unit and the phase of pulse waves from a location other than the forehead of the subject that were detected by the second pulse wave detection unit, the phase of pulse waves of the ocular fundus of the subject; and an imaging timing control unit that controls, on the basis of the phase of the pulse waves of the ocular fundus of the subject, the timing for imaging the ocular fundus the subject.

IPC Classes  ?

• A61B 3/14 - Arrangements specially adapted for eye photography

Abstract

The present invention is provided with: a waist part (2) disposed around the waist of a user (U); and a front body section (5) positioned under the waist part (2) and covering the front of the user (U). The front body section (5) is provided with: a front body section-main body (51) for covering the lower abdominal region of the user (U); an insertion hole (53) provided in the front body section-main body (51) and formed such that the penis of the user (U) can be inserted therein; and a flap member (60) which is provided attachable to and detachable from the front body section-main body (51) and which, in the attached state, covers the insertion hole (53) and a predetermined region (W) around the insertion hole (53) and, in the detached state, can expose the inserted penis (P) from the insertion hole (53). In the flap member (60), a moisture absorbing part (67) is provided such that the flap member (6) in the attached state can contact the glans (K) of the penis (P) inserted into the insertion hole (53), and absorb and retain moisture.

IPC Classes  ?

• A41B 9/02 - Drawers or underpants for men, with or without inserted crotch or seat parts

Abstract

Provided is a pulse wave detection device comprising: a reflection-type pulse wave sensor having a light-emitting element that projects light onto a test subject, and a light-receiving element that receives the light projected from the light-emitting element and reflected by the test subject; and a biasing member that causes the reflection-type pulse wave sensor to be in close contact with the forehead of the test subject.

IPC Classes  ?

• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow

Abstract

An error determination system for a solar cell module including a plurality of solar cells connected in series comprises: a modulated light emission unit which emits modulated light to one solar cell of the plurality of the solar cells; a phase detection unit which outputs a signal corresponding to the state of the one solar cell on the basis of a signal indicating the power output of the solar cell module and a reference signal indicating the phase (frequency) of the modulated light; and a determination unit which determines whether or not an error has occurred in the one solar cell on the basis of the signal output by the phase detection unit.

IPC Classes  ?

• H02S 50/15 - Testing of PV devices, e.g. of PV modules or single PV cells using optical means, e.g. using electroluminescence
• H02S 10/40 - Mobile PV generator systems

Abstract

A tracheal tube insertion aid kit (1) is used as an aid when inserting a tracheal tube (9) from the oral cavity (B) of a patient (A) through the glottis (D) into the trachea (E) using an indirect glottis viewing-type laryngoscope (2) to which the tracheal tube (9) is not attached. This tracheal tube insertion aid kit (1) is provided with: a guide tube (11) which is flexible and which is configured to be capable of being inserted from the oral cavity (B) through the glottis (D) into the trachea (E); and a guide wire (12) which is capable of being inserted in the guide tube (11) and which is also configured to be capable of being inserted from the oral cavity (B) through the glottis (D) into the trachea (E).

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes

Abstract

2000). The gas and the mixed gas comprises perfluoropropane or perfluorobutane.

IPC Classes  ?

• A61K 49/22 - Echographic preparationsUltrasound imaging preparations
• A61K 31/02 - Halogenated hydrocarbons
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein

Abstract

Provided is a method for sorting a number of samples into an appropriate number of clusters according to their characteristics. Highly-correlated peaks are extracted from mass spectrum data obtained for the samples (S2). Using the extracted peaks, highly-correlated sample pairs are extracted (S3). While removing samples having low degrees of correlation, highly-correlated sample pairs are integrated to form core clusters (S4). Using singular peaks characterizing each core cluster, two or more core clusters are integrated to form clusters (S5-S7). These clusters include mixed clusters in which two or more clusters are mixed. Member determination formulae are created based on the singular peaks of each cluster (S8-S12). All samples, including those which have been excluded from the cluster determination process, are classified into clusters based on the member determination formulae (S14). The member determination formulae can also be used to assign a new sample to one of the cluster.

IPC Classes  ?

• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• H01J 49/00 - Particle spectrometers or separator tubes
• G06F 16/28 - Databases characterised by their database models, e.g. relational or object models
• G16C 20/70 - Machine learning, data mining or chemometrics
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions

Abstract

The present invention provides novel medical means to facilitate glutathione (GSH) synthesis in the brain. These means are miR-96-5p inhibitor increasing GSH expression in the brain and a pharmaceutical composition comprising the miR-96-5p inhibitor and having a preventive and/or therapeutic performance to a disease caused by decrease of GSH amount or depression of GSH activity.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Provided is a cyclodeviation measurement device capable of performing quantitative measurement at low cost and capable of being used not only for diagnosis in an examination room and but also during a surgical operation in a surgical operating room, which has not been considered so far. In addition, provided is an improved device of the above device which can perform cyclodeviation measurement at a position other than the front by stabilizing vision fixation. The cyclodeviation measurement device includes a board, a pair of Maddox rods provided on the board so that at least one Maddox rod is rotatable, a manipulation means capable of freely rotating the rotatable Maddox rod, and an indication means indicating a rotation angle of the Maddox rod. The improved device includes a pair of a Maddox rod and a Bagolini striated lens instead of a pair of the Maddox rods.

IPC Classes  ?

• A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes

Abstract

The present invention provides a novel composition having an antifungal activity without depending on conventional compositions having anticandidal activity or combinations of such compositions. More specifically, the composition according to the present invention having an antifungal activity comprises a complex of lysozyme bonded to chitosan. The composition according to the present invention is applicable to candidiasis of the skin and mucous membranes, in particular, oral candidiasis and vagina candidiasis affecting a large number of patients and can ameliorate the symptoms of these diseases, heal the same and prevent infection of the same. The composition comprises a complex of lysozyme, which has been widely used as a highly safe natural food additive, with a polysaccharide and, therefore, can reassure patients who use the same and ease their burden. The composition according to the present invention comprises a complex of lysozyme, which is a highly safe natural food additive, with a polysaccharide and, therefore, can be safely used by patients without considering any risk.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/722 - ChitinChitosan
• A61P 31/10 - Antimycotics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups